EGFR and neoplasm: ADCs can precisely target tumor cells by combining highly specific monoclonal antibodies with highly toxic cytotoxic drugs, thereby achieving a precise attack on EGFR-TKI-resistant cancer cells and filling the gap between antibody drugs and traditional chemotherapy drugs.